Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases
- Conditions
- Children；Infection
- Interventions
- Drug: anti-infective drugs
- Registration Number
- NCT03643497
- Lead Sponsor
- Beijing Children's Hospital
- Brief Summary
This study is based on the hypothesis that the pharmacokinetics of meropenem and linezolid in severe infectious children are different from mild infectious children and adults. The investigators aim to study the population pharmacokinetics of children receiving the meropenem and linezolid for treatment of severe infectious diseases. In this study, the investigators will detect drug concentration in plasma and cerebrospinal fluid by using residual blood samples of blood and cerebrospinal fluid gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of meropenem and linezolid with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of severe infectious diseases in children. It will also set the foundation for further studies to improve anti- infective drug therapies for severe infectious children.
- Detailed Description
1.Establish population pharmacokinetic (PPK) models of meropenem and linezolid in severe infectious children by nonlinear mixed effect modeling (NONMEM).
1. At different time point after meropenem or linezolid administration, plasma and/or cerebrospinal fluid samples of 100 children will be collected from pediatric intensive care unit (PICU) for each drug. The clinical information includes demography, medication, concentration data, blood biochemical parameters and so on.
2. Plasma and cerebrospinal fluid samples will be tested by high performance liquid chromatography (HPLC).
3. PPK models of meropenem and linezolid will be established by NONMEM program.
4. The reliability and stability of the PPK model will be evaluated by 1000 times of Bootstrap procedure and normalized predictive distribution error(NPDE).
2. Evaluation of the clinical feasibility and safety of individualized dosing.
1. According the results of PPK models, the investigators will use dosages recommended in models to cure severe infectious children in prospective studies. For antibiotic drug, 50 children will be collected.
2. The investigators will compare the therapeutic effects and safety between children with conventional therapies and children with individualized therapies in severe infectious diseases, including proportions of children with effective drug concentration, improvement speed of children, liver and kidney functions of children, adverse reactions of drugs and so on
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 800
- Children (0-18 years old) with anti-infective therapy against severe infectious diseases.
- The anti-infective therapy includes meropenem and linezolid commonly used in children with infectious diseases,
- Children severe infectious diseases include severe pneumonia, sepsis, purulent meningitis and other diseases with severe infection.
- Informed consent signed by the parents and/or guardians
- Anti-infective drugs aren't involved in the therapies of children.
- It is unable to provide complete medical records or the current condition cannot accept the study process.
- Patients are allergic to meropenem or linezolid.
- Parents and/or guardians do not agree to participate in this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Children with the usage of anti-infective drugs anti-infective drugs Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
- Primary Outcome Measures
Name Time Method maximum concentration (Cmax) up to 4 weeks Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose
- Secondary Outcome Measures
Name Time Method half-life (t1/2) up to 4 weeks Half-life is the time required for a quantity to reduce to half its initial value
time to achieve maximum concentration (Tmax) up to 4 weeks Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed
absorption rate constant (ka) up to 4 weeks Ka is the rate constant of drug absorption
elimination rate constant (kel) up to 4 weeks The elimination rate constant is a value used in pharmacokinetics to describe the rate at which a drug is removed from the system
Trial Locations
- Locations (1)
Beijing Children's Hospital of Capital Medical University
🇨🇳Beijing, China